Abstract 96P
Background
Archival storage of blood for single-cell (sc) RNA-Seq involves cryopreservation of peripheral blood mononuclear cells (PBMCs). However, this method excludes granulocytes and requires isolation of viable cells, whose transcriptomes may change due to processing time and technician handling. Hence, this method might overlook important data from temporal collection of clinical specimens. By contrast, blood collection in Qiagen PAXgene Blood RNA tubes is routinely practiced in medical sites without any special processing, and is completed with highly stabilized transcriptomes. Here, we present a novel method for single-nucleus (sn) RNA-Seq nuclei from frozen PAXgene blood as an alternative to PBMCs.
Methods
Fresh blood from healthy donors was collected, frozen in PAXgene tubes and processed by our novel method, which utilizes single-nucleus isolation and CRISPR-based strategy, yielding 3’RNA-Seq data via 10x Genomics’ Chromium platform. PBMCs from the same bloods were processed in parallel.
Results
Data quality evaluation revealed that PBMC transcript detection was higher than PAXgene, yet PAXgene RNA quality might exceed that of PBMCs. Unsupervised clustering was used to define cells and marker gene detection was used to assign cell types in PBMC and PAXgene data. Cell type subpopulations could be identified in PAXgene data, including central- and effector memory cells, and CD14+/16+ monocytes. Importantly, cells clustered based on cell type, indicating that sample biology was not masked by collection method. However, PAXgene specimens were distinct due to robust detection of granulocytes, including neutrophils (30-50% of blood cells). Proportions of PAXgene mononuclear cell populations were not significantly different from donor matched PBMCs. Results indicate that frozen PAXgene blood can be used to generate snRNA-Seq data that is comparable to PBMC scRNA-Seq, while also enabling transcriptomic characterization of granulocytes.
Conclusions
These findings provide preliminary evidence that PAXgene blood collection represents a simple, stable alternative to PBMC cryopreservation that could facilitate high quality, reproducible single-cell genomic profiling in clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AsatraZeneca.
Disclosure
A. Rotem, O. Chaudhary, G. Duclos, P. Gathungu, M. Rao, R. Aguilar, L. Amir-Zilberstein, V. Shankarappa, C. Rands, X. Chen, E. Galery Harbolick, R. Halpin, M. Steinberg, J. Boland, M. Scaltriti, B. Dougherty: Financial Interests, Full or part-time Employment: AstraZeneca.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07